ArticlePLOS global public health2025
Prevalence of rifampicin resistance in pulmonary tuberculosis: A laboratory-based study.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) remains a significant global public health challenge, particularly in low- and middle-income countries. The emergence of rifampicin-resistant tuberculosis further complicates control efforts. Despite national efforts, there are limited data on the prevalence of Mycobacterium tuberculosis and their rifampicin resistance in Ghana, especially at the facility level. This study aimed to determine the prevalence of Mycobacterium tuberculosis and rifampicin resistance among presumptive tuberculosis cases at the Ho Teaching Hospital over a three-year period. The study used a retrospective design and collected secondary data from the Microbiology Laboratory Unit of Ho Teaching Hospital between 2022 and 2024. Data on patient demographics, Mycobacterium tuberculosis detection, and rifampicin resistance were retrieved and analysed using descriptive and inferential statistics. Mycobacterium tuberculosis and rifampicin resistance were identified using the GeneXpert MTB/RIF assay. Statistical analyses were performed using STATA version 15 with statistical significance set at p < 0.05. Out of 2,225 presumptive tuberculosis cases, 203 tested positive for the infection, resulting in an overall prevalence of 9.1% (95% CI: 7.9-10.4). The prevalence was significantly higher among males (12.4%) compared to females (5.7%), and highest among young adults aged 18-24 years (12.8%). Of the 166 Mycobacterium tuberculosis-positive cases tested for rifampicin susceptibility, 3 (1.8%) were resistant. Although rifampicin resistance was more common among females and adults, the differences were not statistically significant. Although the detection rate of rifampicin resistance among newly diagnosed Mycobacterium tuberculosis cases was low (1.8%), it remains a significant public health concern, hence the need for enhancing surveillance systems and prioritising early detection strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.